SEARCH

SEARCH BY CITATION

References

  • ARIAS, M., SAUER-LEHNEN, S., TREPTAU, J., JANOSCHEK, N., THEUERKAUF, I., BUETTNER, R., GRESSNER, A. & WEISKIRCHEN, R. (2003). Adenoviral expression of a transforming growth factor-β1 antisense mRNA is effective in preventing liver fibrosis in bile-duct ligated rats. BMC Gastroenterol., 3, 2941.
  • ATTISANO, L. & WRANA, J.L. (2002). Signal transduction by the TGF-beta superfamily. Science, 296, 16461647.
  • BAYER, E.M., HERR, W., KANZLER, S., WALDMANN, C., MEYER ZUM BUSCHENFELDE, K.H., DIESNE, H.P. & LOHSE, A.W. (1998). Transforming growth factor β1 in autoimmune hepatitis: correlation of liver tissue expression and serum levels with disease activity. J. Hepatol., 28, 803811.
  • BLOBE, G.C., SCHIEMANN, W.P. & LODISH, H.F. (2000). Role of transforming growth factor beta in human disease. N. Engl. J. Med., 342, 13501358.
  • BORDER, W.A. & NOBLE, N.A. (1994). Transforming growth factor β in tissue fibrosis. N. Engl. J. Med., 331, 12861292.
  • BOTTINGER, E.P., FACTOR, V.M., TSANG, M.L., WEATHERBEE, J.A., KOPP, J.B., QIAN, S.W., WAKEFIELD, L.M., ROBERTS, A.B., THORGEIRSSON, S.S. & SPORN, M.B. (1996). The recombinant proregion of transforming growth factor beta1 (latency-associated peptide) inhibits active transforming growth factor beta1 in transgenic mice. Proc. Natl. Acad. Sci. U.S.A., 93, 58775882.
  • BROEKELMANN, T.J., LIMPER, A.H., COLBY, T.V. & MCDONALD, J.A. (1991). Transforming growth factor β1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc. Natl. Acad. Sci. U.S.A., 88, 66426646.
  • CALLAHAN, J.F., BURGESS, J.L., FORNWALD, J.A., GASTER, L.M., HARLING, J.D., HARRINGTON, F.P., HEER, J., KWON, C., LEHR, R., MATHUR, A., OLSON, B.A., WEINSTOCK, J. & LAPING, N.J. (2002). Identification of novel inhibitors of the transforming growth factor β 1 (TGF-β 1) type 1 receptor (ALK5). J. Med. Chem., 45, 9991001.
  • CASSIMAN, D., LIBBRECHT, L., DESMET, V., DENEF, C. & ROSKAMS, T. (2002). Hepatic stellate cell/myofibroblast subpopulations in fibrotic human and rat livers. J. Hepatol., 36, 200209.
  • DENNLER, S., ITOH, S., VIVIEN, D., TEN DIJKE, P., HUET, S. & GAUTHIER, J.M. (1998). Direct binding of Smad3 and Smad4 to critical TGF-B inducible elements in the promoter of human plasminogen activator inhibitor-type1 gene. EMBO J., 17, 30913100.
  • EITZMAN, D.T., MCCOY, R.D., ZHENG, X., FAY, W.P., SHEN, T., GINSBURG, D. & SIMON, R.H. (1996). Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J. Clin. Invest., 97, 232237.
  • FRANZEN, P., TEN DIJKE, P., ICHIJO, H., YAMASHITA, H., SCHULZ, P., HELDIN, C.H. & MIYAZONO, K. (1993). Cloning of a TGF beta type I receptor that forms a heteromeric complex with the TGF beta type II receptor. Cell, 75, 681692.
  • GALLAGHER, T.F., FIER-THOMPSON, S.M., GARIGIPATI, R.S., SORENSON, M.E., SMIETANA, J.M., LEE, D., BENDER, P.E., LEE, J.C., LAYDON, J.T., GRISWOLD, D.E., CHABOT-FLETCHER, M.C., BRETON, J.J. & ADAMS, J.L. (1995). 2,4,5-Triarylimidazole inhibitors of IL-1 biosynthesis. Bioorg. Med. Chem. Lett., 5, 11711176.
  • GELLIBERT, F.J. & MATHEWS, N. (2002). PCT Int. Appl., WO 0266462.
  • GEORGE, J. & CHANDRAKASAN, G. (2000). Biochemical abnormalities during the progression of hepatic fibrosis induced by dimethylnitrosamine. Clin. Biochem., 33, 563570.
  • GEORGE, J., RAMESH RAO, K., STERN, R. & CHANDRAKASAN, G. (2001). Dimethylnitrosamine-induced liver injury in rats: the early deposition of collagen. Toxicology, 156, 129138.
  • GUECHOT, J., POUPON, R.E., GIRAL, P., BALKAU, B., GIBOUDEAU, J. & POUPON, R. (1994). Relationship between procollagen III aminoterminal propeptide and hyaluronan serum levels and histological fibrosis in primary biliary cirrhosis and chronic viral hepatitis C. J. Hepatol., 20, 388393.
  • HUSE, M., CHEN, Y.G., MASSAGUE, J. & KURIYAN, J. (1999). Crystal structure of the cytoplasmic domain of the type I TGFβ receptor in complex with FKBP12. Cell, 96, 425436.
  • INMAN, G., NICOLAS, F., CALLAHAN, J., HARLING, J., GASTER, L., REITH, A., LAPING, N. & HILL, C. (2002). SB-431542 is a potent and specific inhibitor of transforming growth factyor-B superfamily type I activin receptor like kinase (alk) receptor ALK4, ALK5 and ALK7. Mol. Pharmacol., 62, 6574.
  • JAMES, J., BOSH, K.S., ZUYDERHOUDT, F.M.J., HOUTKOOPER, J.M. & VANGOOL, J. (1986). Histomorphometric estimation of volume density of collagen as an indication of fibrosis in rat liver. Histochemistry, 85, 129133.
  • KANZLER, S., BAUMANN, M., SCHIRMACHER, P., DRIES, V., BAYER, E., GERKEN, G., DIENES, H.P. & LOHSE, A.W. (2001). Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-beta. J. Viral Hepatitis, 8, 430437.
  • KOLB, M., MARGETTS, P.J., GALT, T., SIME, P.J., XING, Z., SCHMIDT, M. & GAULDIE, J. (2001). Transient gene expression of decorin in the lung reduces the fibrotic response to bleomycin. Am. J. Respir. Crit. Care Med., 163, 770777.
  • KOPP, J.B., FACTOR, V., MOZES, M., NAGY, P., SANDERSON, N., BOTTINGER, E.P., KLOTMAN, P. & THORGEIRSSON, S. (1996). Transgenic mice with increased plasma levels of TGF-β1 develop progressive renal disease. Lab. Invest., 74, 9911003.
  • KUNASAGI, K., INOUE, H., ISHIDOU, Y., MISHIMA, H.K., KAWABATA, M. & MIYAZONO, K. (2000). Characterisation of a bone morphogenic protein-responsive Smad-binding element. Mol. Cell. Biol., 11, 555565.
  • LAPING, N., GRYGIELKO, E., MATHUR, A., BUTTER, S., BOMBERGER, J., TWEED, C., MARTIN, W., FORNWALD, J., LEHR, R., HARLING, J., GASTER, L., CALLAHAN, J.F. & OLSON, B.A. (2002). Inhibition of transforming growth factor (TGF)-b1-induced extracellular matrix with a novel inhibitor of the TGF-B type 1 receptor kinase activity: SB-431542. Mol. Pharmacol., 62, 5864.
  • LI, D. & FRIEDMAN, S.L. (1999). Liver fibrogenesis and the role of hepatic stellate cells: new insights and prospects for therapy. J. Gastroenterol. Hepatol., 14, 618633.
  • LOPEZ-DE-LEON, A. & RODJKIND, M. (1985). A simple micromethod for collagen and total protein determination in formalin-fixed parrafin embedded sections. J. Histochem. Cytochem., 33, 737743.
  • LUND, L.R., RICCIO, A., ANDREASEN, P.A., NIELSEN, L.S., KRISTENSEN, P., LAIHO, M., SAKSELA, O., BLASI, F. & DANO, K. (1987). Transforming growth factor-beta is a strong and fast acting positive regulator of the level of type-1 plasminogen activator inhibitor mRNA in WI-38 human lung fibroblasts. EMBO J., 6, 12811286.
  • MASSAGUE, J., BLAIN, S.A. & LO, R.S. (2000). TGFβ signaling in growth control, cancer, and heritable disorders. Cell, 103, 295309.
  • MATRISIAN, L.M., GANSER, G.L., KERR, L.D., PELTON, R.W. & WOOD, L.D. (1992). Negative regulation of gene expression by TGF-beta. Mol. Reprod. Dev., 32, 111120.
  • MCDOWELL, E.M. & TRUMP, B.F. (1976). Histological fixatives suitable for diagnostic light and electron microscopy. Arch. Pathol. Lab. Med., 100, 405414.
  • MURPHY, F.R., ISSA, R., ZHOU, X., RATNARAJAH, S., NAGASE, H., ARTHUR, M.J., BENYON, C. & IREDALE, J.P. (2002). Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implication for reversibility of liver fibrosis. J. Biol. Chem., 277, 1106911076.
  • NAKAMURA, T., SAKATA, R., UENO, T., SATA, M. & UENO, H. (2000). Inhibition of transforming growth factor beta prevents progression of liver fibrosis and enhances hepatocyte regeneration in dimethylnitrosamine-treated rats. Hepatology, 32, 247255.
  • OBERHAMMER, F.A., PAVELKA, M., SHARMA, S., TIEFENBACHER, R., PURCHIO, A.F., BURSCH, W. & SCHULTE-HERMANN, R. (1992). Induction of apoptosis in cultured hepatocytes and in regressing liver by transforming growth factor beta 1. Proc. Natl. Acad. Sci. U.S.A., 89, 54085412.
  • OHARA, K. & KUSANO, M. (2002). Anti-transforming growth factor-beta1 antibody improves survival rate following partial hepatectomy in cirrhotic rats. Hepatol. Res., 24, 174183.
  • PARADIS, V., MATHURIN, P., LAURENT, A., CHARLOTTE, F., VIDAUD, M., POYNARD, T., HOANG, C., OPOLON, P. & BEDOSSA, P. (1996). Histological features predictive of liver fibrosis in chronic hepatitis C infection. J. Clin. Pathol., 49, 9981004.
  • PETERS, H., BORDER, W.A. & NOBLE, N.A. (1998). Targeting TGF-beta overexpression in renal disease: maximizing the antifibrotic action of angiotensin II blockade. Kidney Int., 54, 15701580.
  • PHILLIPS, D.J. & DE KRETSER, D.M. (1998). Follistatin: a multifunctional regulatory protein. Front. Neuroendocrinol., 19, 287322.
  • PONTINHA, N., PESSEGUEIRO, H. & BARROS, H. (1999). Serum hyaluronan as a marker of liver fibrosis in asymptomatic chronic viral hepatitis C. Scand. J. Clin. Lab. Invest., 59, 343347.
  • SANDERSON, N., FACTOR, V., NAGY, P., KOPP, J., KONDAIAH, P., WAKEFIELD, L., ROBERTS, A., SPORN, M. & THORGEIRSSON, S. (1995). Hepatic expression of mature transforming growth factor β1 in transgenic mice results in multiple tissue lesions. Proc. Natl. Acad. Sci. U.S.A., 92, 25722576.
  • SAWYER, J.S., ANDERSON, B.D., BEIGHT, D.W., CAMPBELL, R.M., JONES, M.L., HERRON, D.K., LAMPE, J.W., MCCOWAN, J.R., MCMILLEN, W.T., MORT, N., PARSONS, S., SMITH, E.C.R., VIETH, M., WEIR, L.C., YAN, L., ZHANG, F. & YINGLING, J.M. (2003). Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-type I receptor kinase domain. J. Med. Chem., 46, 39533956.
  • SHAH, M., REVIS, D., HERRICK, S., BAILLIE, R., THORGEIRSON, S., FERGUSON, M. & ROBERTS, A. (1999). Role of elevated plasma TGF-beta1 levels in wound healing. Am. J. Pathol., 154, 11151124.
  • SHI, Y. & MASSAGUE, J. (2003). Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell, 113, 685700.
  • SWEAT, F., PUCHTLER, H. & ROSENTHAL, S. (1964). Sirius red F3BA as a stain for connective tissue. Arch. Pathol., 78, 6972.
  • TAKABE, K., WANG, L., LEAL, A.M., MACCONELL, L.A., WIATER, E., TOMIYA, T., OHNO, A., VERMA, I.M. & VALE, W. (2003). Adenovirus-mediated overexpression of follistatin enlarges intact liver of adult rats. Hepatology, 38, 11071115.
  • WANG, Q., WANG, Y., HYDE, D.M., GOTWALS, P.J., KOTELIANSKY, V.E., RYAN, S.T. & GIRI, S.N. (1999). reduction of bleomycin induced lung fibrosis by transforming growth factor beta soluble receptor in hamsters. Thorax, 54, 805812.
  • WEINER, F.R., SHAH, A., BIEMPICA, L., ZERN, M.A. & CZAJA, M.J. (1992). The effects of hepatic fibrosis on Ito cell gene expression. Matrix, 12, 3643.
  • WESTERHAUSEN Jr, D.R., HOPKINS, W.E. & BILLADELLO, J.J. (1991). Multiple transforming growth factor-beta-inducible elements regulate expression of the plasminogen activator inhibitor type-1 gene in Hep G2 cells. J. Biol. Chem., 266, 10921100.
  • WU, J. & NORTON, P. (1996). Animal models of liver fibrosis. Scand. J. Gastroenterol., 31, 11371143.
  • ZHANG, L.P., TAKAHARA, T., YATA, Y., FURUI, K., JIN, B., KAWADA, N. & WATANABE, A. (1999). Increased expression of plasminogen activator and plasminogen activator inhibitor during liver fibrogenesis of rats: role of stellate cells. J. Hepatol., 31, 703711.
  • ZIYADEH, F., HOFFMAN, B., HAN, D.C., IGLESIAS-DE LA CRUZ, M., CRUZ, M., HONG, S.W., ISONO, M., CHEN, S., MCGOWAN, T. & SHARMA, K. (2000). Long term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor -β antibody in db/db diabetic mice. Proc. Natl. Acad. Sci. U.S.A., 97, 80158020.